Item
Russian-developed COVID-19 Vaccine Interim Trial Reports 92% Success Rate
Title (Dublin Core)
Russian-developed COVID-19 Vaccine Interim Trial Reports 92% Success Rate
Description (Dublin Core)
Following initial findings of Pfizer's vaccine being effective in preventing COVID-19 infection in more than 90% of people, Russia says its vaccine has 92% efficacy according to preliminary findings in stage three of the clinical trials. The trial results are based on 20 confirmed COVID-19 cases.
Date (Dublin Core)
Creator (Dublin Core)
Contributor (Dublin Core)
Event Identifier (Dublin Core)
Partner (Dublin Core)
Type (Dublin Core)
screenshot
Link (Bibliographic Ontology)
Controlled Vocabulary (Dublin Core)
English
Health & Wellness
English
Public Health & Hospitals
Curator's Tags (Omeka Classic)
Collection (Dublin Core)
English
Vaccine Stories
Linked Data (Dublin Core)
Date Submitted (Dublin Core)
11/12/2020
Date Modified (Dublin Core)
11/13/2020
1/31/2021
03/15/2021
Date Created (Dublin Core)
11/11/2020
This item was submitted on November 12, 2020 by Tina Chang using the form “Share Your Story” on the site “A Journal of the Plague Year”: http://mail.covid-19archive.org/s/archive
Click here to view the collected data.